Takashi Sakamoto

Dr. Takashi Sakamoto

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
HWHsin-Chieh Wu
Hsin-Chieh Wu
DRDomitille Rérolle
Domitille Rérolle
CBCaroline Berthier
Caroline Berthier
RHRita Hleihel
Rita Hleihel
TSTakashi Sakamoto
Takashi Sakamoto
HTHugues de Thé
Hugues de Thé
Acute myeloid leukemia (AML) pathogenesis often involves a mutation in the NPM1 nucleolar chaperone, but the bases for its transforming properties and overall association with favorable therapeutic responses remain incompletely understood. Here we demonstrate that an oncogenic mutant form of NPM1 (NPM1c) impairs mitochondrial function. NPM1c also hampers formation of promyelocytic leukemia (PML) nuclear bodies (NB), which are regulators of mitochondrial fitness and key senescence effectors. Actinomycin D (ActD), an antibiotic with unambiguous clinical efficacy in relapsed/refractory NPM1c-AMLs, targets these primed mitochondria, releasing mitochondrial DNA, activating cyclic GMP-AMP synthase signaling, and boosting reactive oxygen species (ROS) production. The latter restore PML NB formation to drive TP53 activation and senescence of NPM1c-AML cells. In several models, dual targeting of mitochondria by venetoclax and ActD synergized to clear AML and prolong survival through targeting of PML. Our studies reveal an unexpected role for mitochondria downstream of NPM1c and implicate a mitochondrial/ROS/PML/TP53 senescence pathway as an effector of ActD-based therapies.Significance: ActD induces complete remissions in NPM1-mutant AMLs. We found that NPM1c affects mitochondrial biogenesis and PML NBs. ActD targets mitochondria, yielding ROS which enforce PML NB biogenesis and restore senescence. Dual targeting of mitochondria with ActD and venetoclax sharply potentiates their anti-AML activities in vivo.This article is highlighted in the In This Issue feature, p. 2945

9 May 2009 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
TSTakashi Sakamoto
Takashi Sakamoto
KYKouhei Yamashita
Kouhei Yamashita
CMChisaki Mizumoto
Chisaki Mizumoto
MUMaki Ueda
Maki Ueda
TTTomoharu Takeoka
Tomoharu Takeoka
TOTatsuharu Ohno
Tatsuharu Ohno

16 May 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
TSTakashi Sakamoto
Takashi Sakamoto
JLJulie Leca
Julie Leca
XZXin Zhang
Xin Zhang
CMCem Meydan
Cem Meydan
JFJonathan Foox
Jonathan Foox
TMTak W. Mak
Tak W. Mak
In human acute myeloid leukemia (AML), mutations of isocitrate dehydrogenase-1 ( IDH1 ) often co-occur with NPM1 mutations, and less frequently with FLT3 mutations. To investigate whether the effects of IDH1 mutation differ according to the specific co-occurring mutation, we generated two strains of double knock-in mutant mice. Idh1 R132H combined with Npm1c induced overt AML, whereas Idh1 R132H plus Flt3 ITD resulted in Flt3 ITD -driven myelo- or lymphoproliferation that was minimally affected by Idh1 R132H and rarely generated AML. Gene expression profiling revealed differences between Idh1 R132H ; Npm1c cells and Idh1 R132H ; Flt3 ITD cells and suggested altered heme metabolism and immune responses in the former. The profile of Idh1 R132H ; Npm1c cells corresponded to that of human IDH -mutated AML cells, particularly those resistant to inhibitors of mutant IDH. Compared to treatment with a menin inhibitor, IDH1-targeted therapy of Idh1 R132H ; Npm1c AML-bearing mice was less efficacious in improving cell differentiation and extending survival. The differential cooperation of Idh1 R132H with Npm1c vs. Flt3 ITD may have implications for the devising of subtype-specific treatments for human AML.

21 March 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MSMaki Sakurada-Aono
Maki Sakurada-Aono
TSTakashi Sakamoto
Takashi Sakamoto
MKMasayuki Kobayashi
Masayuki Kobayashi
YTYoko Takiuchi
Yoko Takiuchi
FIFumie Iwai
Fumie Iwai
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo

18 January 2026 in Cytotherapy
Verified
Journal Article
Open access
YTYusuke Tashiro
Yusuke Tashiro
TJTomoyasu Jo
Tomoyasu Jo
TKToshio Kitawaki
Toshio Kitawaki
NYNoriyoshi Yoshinaga
Noriyoshi Yoshinaga
TSTakashi Sakamoto
Takashi Sakamoto
YAYasuyuki Arai
Yasuyuki Arai
Chimeric antigen receptor (CAR)-T cell therapies targeting CD19 have shown efficacy against B-cell malignancies. However, they frequently cause immune effector cell-associated neurotoxicity syndrome (ICANS), which can be life-threatening and require intensive care. Even when it is not severe, ICANS can lead to prolonged hospitalization and limit treatment options, especially for elderly patients. Despite its clinical significance, a reliable, early predictive marker for ICANS has not been identified. To identify risk factors for ICANS, we retrospectively analyzed B-cell lymphoma patients who received tisagenlecleucel (tisa-cel), lisocabtagene maraleucel (liso-cel), or axicabtagene ciloleucel (axi-cel) at Kyoto University Hospital from 2019 to 2024. Among 106 patients, 76 received tisa-cel, 22 liso-cel, and eight axi-cel. Median age at infusion was 63.5 years (interquartile range, 57-69). Eight patients (8%) had a history of central nervous system (CNS) involvement. ICANS occurred in 17 patients (16%), all with prior cytokine-release syndrome (CRS). Reticulocyte counts at infusion were significantly lower in patients who subsequently developed ICANS (1.57 versus 2.80 × 104/μL, P < 0.01). Multivariate analysis identified a low reticulocyte count at infusion (HR, 3.67; 95% CI, 1.23-11.02; P = 0.02), history of CNS involvement (HR 8.37; 95% CI, 3.04-23.04; P < 0.01), and axi-cel (HR, 4.56; 95% CI, 1.88-11.09; P < 0.01) as independent risk factors. Patients divided by the median reticulocyte count at infusion (2.57 × 104/μL) demonstrated significantly higher 30-day cumulative incidence of ICANS in those with lower counts (25.5% versus 7.8% at 30 days; P = 0.018). Reticulocyte counts at infusion, a simple hematological parameter, may help predict ICANS development and guide optimal risk-based management of chimeric antigen receptor (CAR)-T cell therapy.

10 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YOYusuke Okamoto
Yusuke Okamoto
MKMasayuki Kobayashi
Masayuki Kobayashi
TSTakashi Sakamoto
Takashi Sakamoto
KSKotaro Shirakawa
Kotaro Shirakawa
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
Replication stress (RS) represents a major vulnerability of cancer cells treated with nu-cleoside analogs and related antimetabolites; however, tumors frequently acquire tol-erance mechanisms that permit survival despite persistent DNA lesions. This review examines molecular determinants of RS tolerance, focusing on human T-cell leukemia virus type 1 (HTLV-1)–mediated adult T-cell leukemia/lymphoma (ATL) as a model of virus-mediated rewiring of DNA damage responses. Chain-terminating nucleoside an-alogs generate aberrant replication intermediates, including blocked 3’ DNA termini, mis-incorporated bases, and stalled replication forks. In ATL, viral oncoproteins suppress key components of replication stress response pathways, notably tyrosyl-DNA phos-phodiesterase 1 (TDP1) and mismatch repair (MMR), thereby creating exploitable repair deficiencies. Consistent with this vulnerability, ATL cells exhibit marked sensitivity to replication stress–inducing agents such as irinotecan (CPT-11) and the chain-terminating nucleoside analog abacavir. Recent CRISPR-based functional genomics studies further identify Schlafen 11 (SLFN11) as an independent and dominant regulator of RS sensitivity. SLFN11 determines the fate of stressed replication forks independently of lesion pro-cessing, acting as an execution factor that converts otherwise tolerable RS into irreversible replication arrest. We conclude by discussing therapeutic strategies that exploit RS tol-erance defects in ATL, including biomarker-guided nucleoside analog therapy, and ra-tional combination approaches targeting compensatory RS pathways.